Introduction
During the past three decades, BMT and transplantation of PBSCs have become a well-established treatment procedure for many malignant and nonmalignant disorders in both children and adult patients. However, rejection and relapse remain the most important risks, which may counteract the success of allo-SCT. Donor lymphocyte infusion (DLI) following chemotherapy is an instrument of increasing importance to treat or to prevent overt relapse since Kolb et al. 1 have first shown its efficacy in patients with CML relapsing after allo-SCT. Since then, experience with immunotherapy has shown that DLI initiated during frank hematologic relapse induces CR in 8% of patients with ALL and in 22% of patients with AML. 2 If tumor burden is reduced by chemotherapy before DLI, the rate of complete response is significantly improved (to 33% in ALL and 37% in AML). 3 These results suggest that immunotherapy offers the greatest benefit to patients with acute leukemia following SCT, when it is administered before the occurrence of hematologic relapse. Therefore, it is desirable to identify early patients who are at greatest risk of relapse, so that additional immunotherapy can be delivered as prophylaxis. Immunotherapy after allo-SCT may, therefore, be useful in increasing the alloreactive potential of the graft and augmenting a possible GVL effect. Additionally, the implementation of treatment in an early phase of impending relapse offers the possibility of using cessation of CsA or low-dose DLI, which may be less likely to cause severe GvHD. 4 The GVL response is thought to be a complex, multistep process that involves activation of donor T cells by Ags, clonal expansion of the activated T cells and differentiation of these cells into helper or cytotoxic effectors. Therefore, clonal expansion of transfused T cells is not likely to occur before 3-4 weeks after transfusion. This delay could allow rapidly evolving leukemia cells to proliferate and progress to overt relapse before the GVL effect is augmented by the donor graft.
The identification of the patients at risk for relapse or graft rejection can be perfectly performed by using the instruments of chimerism analysis, that is, the investigations of the genotypic origin of post-transplant hematopoiesis. 'Chimera' refers to Greek mythology where Homer described a fire-spitting monster with the head of a lion, the body of a goat and the tail of a serpent. Examining this question, we learned that the development of a mixed increasing chimerism (that is, the re-increase of the recipient hematopoiesis) is an early sign of a pending relapse. We suggested that a preemptive treatment guided by chimerism analysis could be more successful than the treatment of an overt relapse. 5, 6 In the last 10 years, we studied systematically the role of changing chimerism and the treatment possibilities in various diseases. In a prospective multicenter study in 163 children with ALL following allo-SCT, hematopoietic chimerism was analyzed serially and quantitatively using a fluorescent-based short-tandem repeat-PCR. 7 In all, 101 patients revealed complete chimerism (CC) or low-level mixed chimerism (MC) (CC/low-level MC); increasing MC was found in 46 patients; and decreasing MC in 16 patients. Relapse was significantly more frequent in patients with increasing MC (26/46) than in patients with CC/low-level MC (8/101) or in patients with decreasing MC (0/16; Pp0.0001). The probability of 3-year EFS was 54% for all patients, 66% for patients with CC/low-level MC (n ¼ 101), 66% for patients with decreasing MC (n ¼ 16) and 23% for patients with increasing MC (n ¼ 46; Pp0.0001). Of the 46 patients with increasing MC, 31 received immunotherapy. This group had a significantly higher 3-year EFS estimate (37%) than the 15 patients who did not receive immunotherapy (0%; Pp0.001). Immunotherapy for patients receiving CsA consisted of immediate discontinuation of the immunosuppressive agent. Chimerism was then assayed weekly until CC status was restored. If MC continued to increase after cessation of CsA, a DLI was given. Immunotherapy for patients not receiving CsA consisted of DLI as frontline treatment. The cell dose administered was based on the number and potential severity of HLA mismatches between the donor and recipient, and ranged from 2.5 Â 10 4 to 1 Â 10 6 /kg of body weight (BW). After DLI, chimerism status was assayed weekly until CC status was restored. Patients who showed a further increase in MC were given an additional DLI after at least 3 weeks had elapsed (see Figure 1) . After the chimerism, the leukemia burden plays an important role for the efficacy of DLI. It could be shown in children transplanted for ALL that the level of minimal residual disease (MRD) prior to transplant has a significant impact on post-transplant outcome. Patients with high-level MRD at the time of transplant (X10 À3 malignant cells in the background of nonmalignant cells) could be rarely cured. Most likely, neither the conditioning nor the alloreactive potential of the graft could clear the disease. In this group, relapse is also occurring although patients are complete chimeras throughout the follow-up. On the other hand, in patients who have a low MRD burden (o10 À3 malignant cells in the background of nonmalignant cells), residual disease can be controlled by a conversion of MC to CC, for example, by preemptive immunotherapy. 8 In a multicenter study in AML, a total of 81 children were monitored; 62 patients revealed CC, low-level MC or decreasing MC. Increasing MC was detected in 19 cases. Despite early immunological intervention, relapse was still significantly more frequent in patients with increasing MC (9/19) than in patients with CC, low-level or decreasing MC (8/62, Po0.005). The probability of 3-year EFS was 52% for all patients (n ¼ 81); 59% for patients with CC and lowlevel MC; 60% for patients with decreasing MC (n ¼ 62); and 28% for patients with increasing MC (n ¼ 19, Po0.005). Patients with increasing MC who received early immunological intervention showed a significantly enhanced pEFS (probability for EFS 36%, n ¼ 15) compared with patients with increasing MC without intervention (pEFS 0%, n ¼ 4, P ¼ 0.05). These results demonstrated that also pediatric AML patients with increasing MC are at highest risk for relapse and that early immunological intervention can prevent relapse in these patients (Figure 2 ). 9 The value of DLI had also been studied in JMML (juvenile myelomonocytic leukemia). In all, 21 patients with JMML who received DLI after allo-SCT for either MC (n ¼ 7) or relapse (n ¼ 14) were studied. Six patients had been transplanted from an HLA-matched sibling and 15 from other donors. Six of the 21 patients responded to DLI: the probability to respond was higher in patients with MC (3/7) than in patients with open relapse (3/14). Response rate was significantly higher in patients receiving a higher total T-cell dose (X1 Â 10 7 /kg). None of the six patients receiving DLI from a matched sibling responded. Response was observed in 5/6 patients who did and in 1/15 children who did not develop acute GvHD following DLI /kg BW. In all, 11/15 remained in CR and 1/15 patients developed GvHD grade III that turned out to extensive chronic GvHD. Preemptive immunotherapy with DLI, administered on the basis of increasing MC, is feasible and might prevent graft rejection.
11 Figure 3 demonstrates the influence of DLI on the chimerism state in a patient with SAA.
Conclusions
Donor lymphocyte infusion given after an allo-SCT is a powerful tool that may help to prevent or treat graft rejection, relapse or infection. On the other hand, it may also be harmful for the patient and cause aplasia and/or acute GvHD. Many studies have shown that DLI is more effective when given in an early stage of disease and/or in diseases that are progressing slowly. In this sense, chronic myeloid leukemia has proven to be a better target than acute leukemia. Chimerism analysis may help to use this instrument in an optimized way enabling us to survey engraftment and graft function. Chimerism analysis can serve as an indicator for impending graft rejection or recurrence of the underlying disease. Therefore, in our hands, chimerism analysis has become the platform for preemptive immunotherapy and, in particular, DLI. We could demonstrate the effect of chimerism-guided DLI treatment strategy in patients with ALL, AML, JMML and nonmalignant diseases.
Future perspectives
There is increasing evidence that the levels of minimal resting leukemia cells before [13] [14] [15] and after 16 SCT play an important role in defining the risk of relapse after allo-SCT. However, prospectively tested strategies to intervene in the case of upcoming MRD signals after allo-SCT are still missing. 17 Unfortunately, the repertoire of possible tested tools is still small. Most strategies have been tested in vitro only as CTLs, DCs and the expression of leukemia-specific Ags such as the proteinase PR-3 or the zinc-finger transcription factor Wilm's tumour-1 protein. 18 Therefore, within the EBMT Paediatric Working Party, a combined effort to study the role of MRD for guiding preemptive relapse treatment and the differentiated analysis of possible strategies is needed. /kg body weight (BW) CD3-positive T cells on day þ 60, and after a second increase of autologous proportions up to 80% at day þ 189. He responded to both DLI series, and remained in continuous complete remission with a stable MC below 20%. 12 
